Ascendis Pharma A/S (NASDAQ:ASND) Upgraded at StockNews.com

StockNews.com upgraded shares of Ascendis Pharma A/S (NASDAQ:ASND) from a sell rating to a hold rating in a research note released on Thursday.

Several other research firms have also issued reports on ASND. Morgan Stanley increased their price objective on shares of Ascendis Pharma A/S from $116.00 to $140.00 and gave the stock an equal weight rating in a research report on Thursday, May 16th. Wells Fargo & Company increased their price target on Ascendis Pharma A/S from $260.00 to $262.00 and gave the company an overweight rating in a report on Friday, May 3rd. Cantor Fitzgerald restated an overweight rating and set a $173.00 price objective on shares of Ascendis Pharma A/S in a research note on Wednesday, May 15th. Citigroup increased their target price on Ascendis Pharma A/S from $146.00 to $182.00 and gave the company a buy rating in a research note on Thursday, February 8th. Finally, Wedbush boosted their price target on Ascendis Pharma A/S from $207.00 to $225.00 and gave the stock an outperform rating in a research report on Thursday, February 8th. Two analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat.com, Ascendis Pharma A/S currently has a consensus rating of Moderate Buy and a consensus price target of $176.88.

Ascendis Pharma A/S Stock Up 0.7 %

Shares of NASDAQ ASND opened at $130.41 on Thursday. The stock has a market capitalization of $7.59 billion, a PE ratio of -13.57 and a beta of 0.54. The firm has a fifty day moving average of $140.23 and a 200-day moving average of $131.86. Ascendis Pharma A/S has a 52-week low of $83.75 and a 52-week high of $161.00.

Ascendis Pharma A/S (NASDAQ:ASND) last posted its quarterly earnings results on Thursday, May 2nd. The biotechnology company reported ($2.48) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.57) by ($0.91). The firm had revenue of $103.11 million for the quarter, compared to analysts’ expectations of $85.72 million. Ascendis Pharma A/S had a negative net margin of 152.68% and a negative return on equity of 16,574.15%. Equities research analysts expect that Ascendis Pharma A/S will post -5.03 EPS for the current fiscal year.

Institutional Trading of Ascendis Pharma A/S

A number of hedge funds have recently made changes to their positions in the stock. Signaturefd LLC grew its holdings in Ascendis Pharma A/S by 31.9% during the 3rd quarter. Signaturefd LLC now owns 798 shares of the biotechnology company’s stock worth $75,000 after acquiring an additional 193 shares in the last quarter. Barclays PLC grew its position in shares of Ascendis Pharma A/S by 2,775.3% in the 3rd quarter. Barclays PLC now owns 17,482 shares of the biotechnology company’s stock worth $1,637,000 after acquiring an additional 16,874 shares in the last quarter. J.P. Morgan Private Wealth Advisors LLC acquired a new position in shares of Ascendis Pharma A/S in the 3rd quarter worth approximately $1,810,000. Values First Advisors Inc. raised its position in shares of Ascendis Pharma A/S by 3.2% during the 3rd quarter. Values First Advisors Inc. now owns 10,235 shares of the biotechnology company’s stock valued at $958,000 after acquiring an additional 314 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA lifted its stake in Ascendis Pharma A/S by 16.3% during the third quarter. Massachusetts Financial Services Co. MA now owns 1,264,470 shares of the biotechnology company’s stock worth $118,405,000 after purchasing an additional 176,948 shares during the last quarter.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.